Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 0.80 |
| ▸ | PTK2B | Q14289 | 6/20 | 0.80 |
| ▸ | ULK1 | O75385 | 2/20 | 0.70 |
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | CDK7 | P50613 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207981 | 0.94 | PTK2 (0.88) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL3159353 | 0.89 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5209315 | 0.88 | PTK2 (0.88) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5208623 | 0.88 | PTK2 (0.73) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5215829 | 0.86 | PTK2 (0.70) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5209509 | 0.86 | PTK2 (0.80) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5210663 | 0.85 | PTK2 (0.89) | PTK2PTK2BCDK1CDK7AURKA | |
| SCHEMBL21664493 | 0.83 | PTK2 (0.79) | PTK2PTK2B | |
| SCHEMBL5212849 | 0.83 | PTK2B (0.82) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL21649593 | 0.83 | PTK2 (0.80) | PTK2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | claimed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, CCNA1 | PTK2 3610/4885PTK2B 3168/4885ULK1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.